Vyvanse FDA Approval History

Initial Approval: ADHD in Children (February 2007)

The FDA granted approval to NDA 021977 on February 23, 2007, making Vyvanse the first lisdexamfetamine product available in the United States [1]. The indication covered ADHD in patients aged 6 through 12 years. New River Pharmaceuticals, a small Virginia-based firm, held the original NDA.

The key trial was a randomized, double-blind, placebo-controlled, analog-classroom study in 290 children aged 6 to 12. Participants received lisdexamfetamine 30 mg, 50 mg, or 70 mg once daily, or placebo. At the primary endpoint, all three active doses produced statistically significant reductions in SKAMP (Swanson, Kotkin, Agler, M-Flynn, and Pelham) deportment scores compared with placebo (P<0.001 for each dose group) [2]. Effect sizes were large, ranging from 1.13 to 1.40 across the dose range.

The approval was notable for the drug's prodrug mechanism. Lisdexamfetamine itself is pharmacologically inactive. It requires enzymatic cleavage of the lysine moiety by red blood cell aminopeptidases to release active d-amphetamine [3]. This design was intended to produce a more consistent pharmacokinetic profile and a lower potential for non-oral misuse compared with immediate-release amphetamine formulations.

Shire Pharmaceuticals acquired New River in April 2007 for $2.6 billion, just weeks after the FDA decision, gaining full commercial rights to the drug [1].

Expansion to Adult ADHD (2008)

In April 2008, the FDA broadened the Vyvanse label to include treatment of ADHD in adults aged 18 and older [1]. This made lisdexamfetamine one of the few stimulant medications with a specific adult ADHD indication at the time.

The supporting data came from two phase III trials. The first, a four-week randomized controlled trial in 420 adults, demonstrated that lisdexamfetamine at 30 mg, 50 mg, and 70 mg per day significantly improved ADHD-RS-IV total scores versus placebo. Mean improvement from baseline was 16.2 points for the 70 mg group compared with 8.2 points for placebo [4]. A second forced-dose titration study confirmed efficacy across the approved dose range and showed that the drug's effect lasted at least 14 hours post-dose in adult subjects [5].

The adult label carried the same boxed warning as the pediatric indication, cautioning about the high potential for abuse and dependence consistent with all Schedule II amphetamine products. No new safety signals emerged from the adult trials.

Prodrug Design and Abuse-Deterrent Pharmacology

Lisdexamfetamine's prodrug architecture was a deliberate regulatory strategy. It does not fit the FDA's formal "abuse-deterrent formulation" category (which applies primarily to opioids), but the pharmacokinetic data submitted to the agency showed a blunted Cmax and delayed Tmax when the drug was administered intranasally or intravenously compared with equivalent doses of d-amphetamine [3].

In a human abuse liability study (N=36 stimulant abusers), intravenous lisdexamfetamine 50 mg produced significantly lower "Drug Liking" VAS scores than intravenous d-amphetamine 20 mg (P<0.05) [6]. The FDA permitted specific language in Section 9 of the label noting that lisdexamfetamine "produced subjective responses on abuse-related measures that were less than d-amphetamine when administered intravenously" [1].

This distinction matters clinically. The drug still carries Schedule II classification, and the DEA treats it identically to other amphetamines for prescribing and dispensing purposes. Prescribers should not interpret the prodrug design as a guarantee against diversion. Dr. Timothy Wilens of Massachusetts General Hospital stated in a 2010 review that "the prodrug mechanism may reduce, but does not eliminate, the abuse liability of amphetamine-class stimulants" [7].

Binge Eating Disorder Indication (January 2015)

On January 30, 2015, the FDA approved lisdexamfetamine for moderate-to-severe BED in adults, making it the first (and, as of 2026, the only) medication with this specific FDA indication [8]. The supplemental NDA (sNDA 208510) was reviewed under standard review.

Three randomized, placebo-controlled trials supported the BED indication. The two identical key trials (Study 1 and Study 2) enrolled a combined 724 adults with moderate-to-severe BED (defined as 3 or more binge eating days per week). In Study 1, lisdexamfetamine 50 mg and 70 mg reduced mean binge eating days per week from 4.8 at baseline to 0.9 and 0.7, respectively, versus 2.3 for placebo at 12 weeks [9]. The 70 mg dose produced a cessation rate (defined as zero binge days in the final 28 days) of 40% versus 15% for placebo. Study 2 replicated these findings, with 50 mg and 70 mg doses both statistically superior to placebo on all primary and key secondary endpoints [9].

The approved BED dose range was 50 mg to 70 mg daily. The label explicitly states that Vyvanse is "not indicated for weight loss," and the FDA required this language after the advisory committee expressed concern that the drug could be misused for weight management [8]. The BED approval did not extend to children or adolescents.

A long-term maintenance study (N=275) further demonstrated that patients who responded to open-label lisdexamfetamine and were then randomized to continue active treatment had a significantly lower relapse rate (3.7%) than those switched to placebo (32.1%) over 38 weeks [10].

Post-Market Safety Surveillance

Since initial approval, the FDA has issued several safety-related label updates based on post-market surveillance data.

Cardiovascular warnings. The label was updated to reflect findings from large observational studies examining stimulant use and cardiovascular events. A 2011 FDA-sponsored cohort study using the Sentinel System analyzed data from over 150,000 stimulant users and found no statistically significant increase in the risk of serious cardiovascular events (myocardial infarction, stroke, or sudden cardiac death) compared with non-users (adjusted hazard ratio 0.83 to 95% CI 0.72 to 0.96) [11]. The agency maintained the existing cardiovascular precaution language but did not add new restrictions.

Psychiatric adverse events. The class labeling for amphetamine products includes warnings about treatment-emergent psychosis and mania. A 2019 analysis published in the New England Journal of Medicine found that amphetamine users had a higher incidence of new-onset psychosis than methylphenidate users (adjusted risk ratio 1.65 to 95% CI 1.31 to 2.09), prompting increased attention to psychiatric monitoring during stimulant therapy [12].

Serotonin syndrome. In 2016, the FDA added serotonin syndrome to the warnings section for all amphetamine products, including Vyvanse, based on post-market case reports of interactions with serotonergic medications such as SSRIs, SNRIs, and triptans [13].

Growth suppression in children. Long-term extension data showed mean growth suppression of approximately 1.4 cm in height and 2.7 kg in weight relative to normative growth curves after 24 months of continuous treatment in children [5]. The label recommends periodic monitoring of height and weight during treatment.

Label Updates and Formulation Changes

The Vyvanse label has undergone multiple revisions since 2007. Key non-safety changes include:

In 2017, the FDA approved a chewable tablet formulation in strengths of 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, and 60 mg [1]. This expanded options for patients who have difficulty swallowing capsules. The bioequivalence data showed that the chewable tablets met the FDA's 80% to 125% confidence interval criteria versus the reference capsule formulation when administered under fed conditions.

Wigal et al. (2017) published a comprehensive review of the long-term efficacy and safety profile of lisdexamfetamine across age groups, synthesizing data from trials spanning up to four years of treatment. Their analysis confirmed sustained efficacy on ADHD-RS scores and a safety profile consistent with the stimulant class, with the most common adverse events being decreased appetite (39%), insomnia (23%), and dry mouth (21%) in adults [14].

The 2020 label revision updated the drug interaction section to include monoamine oxidase inhibitors (MAOIs), which are contraindicated within 14 days of lisdexamfetamine use. The revision also clarified dosing in patients with severe renal impairment (GFR <30 mL/min/1.73 m²), recommending a maximum dose of 50 mg/day [1].

Generic Entry and Market Competition (2023)

Vyvanse's exclusivity story was complex. Takeda (which acquired Shire in 2019 for $62 billion) held multiple patents, but the primary composition-of-matter patent expired in February 2023. An authorized generic from Takeda subsidiary Alvogen launched on August 18, 2023 [15].

Several other generic manufacturers received ANDA approvals and entered the market in 2023 and 2024, including Teva, Sandoz, and Dr. Reddy's. The entry of generics reduced average wholesale prices by approximately 50% to 60% within the first six months [15].

During its period of market exclusivity, Vyvanse generated peak annual U.S. sales of $4.2 billion in 2022, making it one of the highest-grossing branded stimulant medications in history [15]. Total prescriptions in 2022 exceeded 17.5 million, reflecting both the ADHD and BED indications.

The generic formulations are rated AB to the reference listed drug, meaning the FDA considers them therapeutically equivalent and interchangeable at the pharmacy level. Clinicians should be aware that some patients may report subjective differences when switching from branded to generic products, though bioequivalence standards require demonstration of equivalent rate and extent of absorption.

Current Label Summary and Clinical Considerations

The 2026 prescribing information for lisdexamfetamine includes three approved indications: ADHD in patients aged 6 and older, ADHD in adults, and moderate-to-severe BED in adults [1]. The starting dose for ADHD is 30 mg once daily in the morning, titrated in increments of 10 mg or 20 mg at weekly intervals, with a maximum of 70 mg/day.

The American Academy of Pediatrics (AAP) 2019 clinical practice guideline lists stimulant medications, including lisdexamfetamine, as first-line pharmacotherapy for ADHD in children aged 6 and older [16]. The guideline recommends that clinicians titrate to achieve "maximum benefit with tolerable side effects," checking vital signs at each dose adjustment.

For the BED indication, the recommended starting dose is 30 mg/day, titrated to a target range of 50 mg to 70 mg/day. The label notes that the drug has not been studied in combination with other BED therapies, and clinicians should reassess the need for continued treatment periodically.

Prescribers must use a DEA-registered prescriber number and follow state-specific rules for Schedule II prescriptions, which in most states require a new written prescription for each fill with no refills. Electronic prescribing of controlled substances (EPCS) is now mandatory in many states, including New York and Texas, and available in all 50 states [17].